ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Clinical Effect of Daily Next Science™ Acne Gel (NAG) on Mild to Moderate Facial Acne

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02404285
Recruitment Status : Completed
First Posted : March 31, 2015
Last Update Posted : March 28, 2017
Sponsor:
Collaborators:
Jacksonville Clinical Research Center
St. Johns Center for Clinical Research
Fleming Island Center for Clinical Research
Information provided by (Responsible Party):
Next Science TM

Brief Summary:
This is a 12 week, multi-site, double-blind, vehicle-controlled study in subjects with mild to moderate facial acne. Subjects will be randomized 1:1 to apply either topical NAG or vehicle gel daily. Subjects will be evaluated for clinical acne and quality of life outcomes at baseline, 2 weeks, 4 weeks, 8 weeks and 12 weeks.

Condition or disease Intervention/treatment Phase
Acne Vulgaris Drug: Next Science Acne Gel Drug: Vehicle Phase 1 Phase 2

Detailed Description:

Sample Size: N= 60 completed subjects Male and female subjects 12 years or older diagnosed with mild to moderate inflammatory facial acne vulgaris.

Subjects will be treated with once daily topical NAG or matching vehicle and will attend screening, randomization, 2,4,8 and 12 week visits. The following will be assessed:

  1. Lesion counts with photography
  2. Investigator Global Assessment
  3. Acne Quality of Life Questionnaire
  4. Treatment Area Assessment by Investigator

Subjects will discontinue all baseline topical acne treatments with a 2 week washout and/or all systemic acne treatments with a 3 week washout. All subjects will be provided open label Cetaphil facial cleanser and double-blind NAG or vehicle product.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 68 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multi-center, Double-blind, Vehicle-controlled Study to Evaluate the Clinical Effect of Daily Next Science™ Acne Gel (NAG) on Mild to Moderate Facial Acne
Study Start Date : March 2015
Actual Primary Completion Date : September 2015
Actual Study Completion Date : September 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Acne

Arm Intervention/treatment
Placebo Comparator: Vehicle

Subjects will be treated with once daily vehicle and will attend screening, randomization, 2,4,8 and 12 week visits. The following will be assessed:

  1. Lesions will be counted and right, left and forward facing photographs will be taken
  2. Investigator Global Assessment
  3. Acne Quality of Life Questionnaire
  4. Treatment Area Assessment by Investigator
Drug: Vehicle
Subjects will be instructed to apply a thin layer of the product to the entire face every evening after washing with Cetaphil cleanser and gently patting the skin dry. Product should not be applied around the eyes or near the mucous membranes. No other acne treatments will be applied to the face during study participation. Hands should be washed following application of study gel.

Active Comparator: NAG (Next Science Acne Gel)

Subjects will be treated with once daily NAG and will attend screening, randomization, 2,4,8 and 12 week visits. The following will be assessed:

  1. Lesions will be counted and right, left and forward facing photographs will be taken
  2. Investigator Global Assessment
  3. Acne Quality of Life Questionnaire
  4. Treatment Area Assessment by Investigator
Drug: Next Science Acne Gel
Subjects will be instructed to apply a thin layer of the product to the entire face every evening after washing with Cetaphil cleanser and gently patting the skin dry. Product should not be applied around the eyes or near the mucous membranes. No other acne treatments will be applied to the face during study participation. Hands should be washed following application of study gel.
Other Name: NAG




Primary Outcome Measures :
  1. Inflammatory lesions [ Time Frame: 12 weeks ]
    Number of inflammatory lesions (papules and pustules) with daily use of NAG compared with vehicle over 12-weeks of use.


Secondary Outcome Measures :
  1. Non-inflammatory lesions [ Time Frame: 12 weeks ]
    Number of non-inflammatory lesions with daily use of NAG compared with vehicle over 12-weeks of use.

  2. Investigator Global Assessment [ Time Frame: 12 weeks ]
    IGA grade (0-5) with daily use of NAG compared with vehicle over 12-weeks of use.

  3. Treatment Areas [ Time Frame: 12 weeks ]

    Erythema will be scored per below:

    Score Assessment Description 0 Absent None

    1. Mild Slight, barely perceptible
    2. Moderate Notable, distinct presence
    3. Severe Intense, marked presence

  4. Treatment Areas [ Time Frame: 12 weeks ]

    Dryness will be scored per below:

    Score Assessment Description 0 Absent None

    1. Mild Slight, barely perceptible
    2. Moderate Notable, distinct presence
    3. Severe Intense, marked presence

  5. Treatment Areas [ Time Frame: 12 weeks ]

    Burning or Stinging will be scored per below:

    Score Assessment Description 0 Absent None

    1. Mild Slight, barely perceptible
    2. Moderate Notable, distinct presence
    3. Severe Intense, marked presence

  6. Treatment Areas [ Time Frame: 12 weeks ]

    Erosion will be scored per below:

    Score Assessment Description 0 Absent None

    1. Mild Slight, barely perceptible
    2. Moderate Notable, distinct presence
    3. Severe Intense, marked presence

  7. Treatment Areas [ Time Frame: 12 weeks ]

    Edema will be scored per below:

    Score Assessment Description 0 Absent None

    1. Mild Slight, barely perceptible
    2. Moderate Notable, distinct presence
    3. Severe Intense, marked presence

  8. Treatment Areas [ Time Frame: 12 weeks ]

    Pain will be scored per below:

    Score Assessment Description 0 Absent None

    1. Mild Slight, barely perceptible
    2. Moderate Notable, distinct presence
    3. Severe Intense, marked presence

  9. Treatment Areas [ Time Frame: 12 weeks ]

    Itching will be scored per below:

    Score Assessment Description 0 Absent None

    1. Mild Slight, barely perceptible
    2. Moderate Notable, distinct presence
    3. Severe Intense, marked presence

  10. Quality of Life assessed by patient-reported Acne Quality of Life questionnaires [ Time Frame: 12 weeks ]
    Subjects will complete the Acne-QoL form at each visit. The Acne-QoL is a validated measure that contains 19 questions referring to the past week, organized into four areas: self-perception, role-social, role-emotional, and acne symptoms. Domain scores are calculated by adding the item scores within each domain, with higher scores reflecting better QoL determination.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female ages 12 and above
  2. Has 10 or more inflammatory lesions on the face (papules and pustules) as determined by qualified examiner at Start of Treatment.
  3. In the area to be treated, has no significant facial dermatological conditions other than acne (as determined by the investigator) that would interfere with any study treatment or procedure
  4. Is willing and able to discontinue use of all baseline acne treatments for the duration of their trial participation
  5. Agrees to refrain from professional facial treatments during their trial participation.
  6. Agrees to avoid tanning booth use and minimize sun exposure during their trial participation.
  7. Is willing and able to follow instructions and procedures including attending scheduled study visits, which will require adequate transportation to the study site
  8. Is able to read, understand and sign the informed consent document and communicate with study staff and investigator. If the subject is a minor, the parent or documented legal guardian must meet these consent requirements and the subject must be able to understand, agree to, and sign the assent form.

Exclusion Criteria:

  1. Has more than 2 nodules/cystic acne lesions on the face
  2. Has a history of significant reactions to topical acne treatments, or a known allergy or hypersensitivity to any listed ingredients
  3. Has any history of skin malignancy
  4. Has significant facial hair that would interfere with evaluation of acne lesions or global assessment.
  5. Has used any systemic medications (including antibiotics, estrogens, retinoids) primarily for treatment of acne in the 21 days prior to randomization.
  6. Has used estrogens primarily as treatment for acne in the 21 days prior to randomization (estrogens prescribed for other reasons will be allowed if stable for at least 30 days prior to randomization).
  7. Has had any professional facial treatments in the 14 days prior to randomization.
  8. Has received any investigational treatment in the 30 days prior to randomization.
  9. Have any significant medical problems or other issues that would, in the investigator's judgment, affect their suitability for participation in this trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02404285


Locations
United States, Florida
Fleming Island Center for Clinical Research
Jacksonville, Florida, United States, 32203
Jacksonville Center for Clinical Research
Jacksonville, Florida, United States, 32216
St. Johns Center for Clinical Research
Ponte Vedra, Florida, United States, 32081
Sponsors and Collaborators
Next Science TM
Jacksonville Clinical Research Center
St. Johns Center for Clinical Research
Fleming Island Center for Clinical Research
Investigators
Study Director: Susan Greco, MD Jacksonville Clinical Research Center
Principal Investigator: Annabelle Matias, MD Fleming Island Center for Clinical Research
Principal Investigator: Lara Church, MD St John's Center for Clinical Research

Publications of Results:
Responsible Party: Next Science TM
ClinicalTrials.gov Identifier: NCT02404285     History of Changes
Other Study ID Numbers: CSP-003
First Posted: March 31, 2015    Key Record Dates
Last Update Posted: March 28, 2017
Last Verified: April 2015

Additional relevant MeSH terms:
Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Sebaceous Gland Diseases